Literature DB >> 7870891

Platelet 5-HT uptake sites in depression: three concurrent measures using [3H] imipramine and [3H] paroxetine.

K M Lawrence1, J Falkowski, R R Jacobson, R W Horton.   

Abstract

Platelet 5-HT uptake sites were measured in 40 depressed patients and 40 controls using [3H] imipramine binding, defined with desmethylimipramine (DMI) and Na+ dependence, and [3H] paroxetine binding. In control subjects the Bmax of DMI defined [3H] imipramine binding was significantly higher than both Na+ dependent [3H] imipramine (by 30%) and [3H] paroxetine binding (by 22%). The Bmax of Na+ dependent [3H] imipramine and [3H] paroxetine binding did not differ significantly. The Kd of Na+ dependent [3H] imipramine binding was significantly lower than the Kd of DMI defined [3H] imipramine binding. The binding of DMI defined and Na+ dependent [3H] imipramine and [3H] paroxetine did not differ significantly between depressed patients and controls in the total group, in those depressed patients and controls in the total group, in those depressed patients who had never taken antidepressants or in those depressed patients who had been recently withdrawn from antidepressants. This study provides no support for the view that the number of platelet 5-HT uptake sites are reduced in depression.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7870891     DOI: 10.1007/bf02246979

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  17 in total

1.  Validity of imipramine platelet binding sites as a biological marker of endogenous depression. A World Health Organization Collaborative Study.

Authors: 
Journal:  Pharmacopsychiatry       Date:  1990-05       Impact factor: 5.788

2.  Development of a rating scale for primary depressive illness.

Authors:  M Hamilton
Journal:  Br J Soc Clin Psychol       Date:  1967-12

3.  3H-imipramine binding to previously frozen platelet membranes from depressed patients, before and after treatment.

Authors:  D Healy; A E Theodorou; A M Whitehouse; K M Lawrence; W White; H Wilton-Cox; S M Kerry; R W Horton; E S Paykel
Journal:  Br J Psychiatry       Date:  1990-08       Impact factor: 9.319

4.  Changes in the binding to platelets of [3H]imipramine and [3H]yohimbine in normal subjects taking amitriptyline.

Authors:  L E Braddock; P J Cowen; J M Elliott; S Fraser; K Stump
Journal:  Neuropharmacology       Date:  1984-02       Impact factor: 5.250

5.  Differentiation of two components of specific [3H]imipramine binding in rat brain.

Authors:  P D Hrdina
Journal:  Eur J Pharmacol       Date:  1984-07-20       Impact factor: 4.432

6.  3H-imipramine binding to freshly prepared platelet membranes in depression.

Authors:  A E Theodorou; C L Katona; S L Davies; A S Hale; S M Kerry; R W Horton; J S Kelly; E S Paykel
Journal:  Psychiatry Res       Date:  1989-07       Impact factor: 3.222

7.  High affinity binding of [3H]paroxetine and [3H]imipramine to human platelet membranes.

Authors:  E T Mellerup; P Plenge; M Engelstoft
Journal:  Eur J Pharmacol       Date:  1983-12-23       Impact factor: 4.432

8.  Human platelets possess multiple [3H]imipramine binding sites.

Authors:  J R Ieni; S R Zukin; H M Van Praag
Journal:  Eur J Pharmacol       Date:  1984-11-27       Impact factor: 4.432

Review 9.  High-affinity 3H-imipramine binding: a new biological marker in depression.

Authors:  S Z Langer; E Zarifian; M Briley; R Raisman; D Sechter
Journal:  Pharmacopsychiatria       Date:  1982-01

10.  Platelet 3H-paroxetine binding in depressed patients.

Authors:  H D'haenen; M De Waele; J E Leysen
Journal:  Psychiatry Res       Date:  1988-10       Impact factor: 3.222

View more
  5 in total

Review 1.  Pathophysiological basis of cardiovascular disease and depression: a chicken-and-egg dilemma.

Authors:  Gilberto Paz-Filho; Julio Licinio; Ma-Li Wong
Journal:  Braz J Psychiatry       Date:  2010-06       Impact factor: 2.697

2.  Brain 5-hydroxytryptamine uptake sites labeled with [3H]paroxetine in antidepressant drug-treated depressed suicide victims and controls.

Authors:  K M Lawrence; F De Paermentier; S Lowther; M R Crompton; C L Katona; R W Horton
Journal:  J Psychiatry Neurosci       Date:  1997-05       Impact factor: 6.186

3.  Platelet serotonergic markers in psychiatric disorders: use, abuse and limitations.

Authors:  P D Hrdina
Journal:  J Psychiatry Neurosci       Date:  1994-03       Impact factor: 6.186

4.  Platelet 5-HT uptake sites, labelled with [3H] paroxetine, in controls and depressed patients before and after treatment with fluoxetine or lofepramine.

Authors:  K M Lawrence; C L Katona; M T Abou-Saleh; M M Robertson; B L Nairac; D R Edwards; T Lock; R A Burns; D A Harrison; R W Horton
Journal:  Psychopharmacology (Berl)       Date:  1994-06       Impact factor: 4.530

5.  Active platelet 5-ht uptake in depressives treated with impramine and ect.

Authors:  P K Dalal; N Lal; J K Trivedi; P K Seth; A K Agarwal; A Khalid
Journal:  Indian J Psychiatry       Date:  1998-01       Impact factor: 1.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.